Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know

Chiara D'Antonio, Annalisa Milano, Riccardo Righini, Concetta Elisa Onesti, Maria Bassanelli, Rosa Falcone, Ida Paris, Salvatore Lauro, Paolo Marchetti

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.

Original languageEnglish
Pages (from-to)5241-5250
Number of pages10
JournalAnticancer Research
Volume34
Issue number10
Publication statusPublished - Oct 1 2014

    Fingerprint

Keywords

  • Cisplatin
  • Gemcitabine
  • Lung cancer chemotherapy
  • Pemetrexed
  • Pharmacogenomic
  • Polymorphism patents
  • Taxanes
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

D'Antonio, C., Milano, A., Righini, R., Onesti, C. E., Bassanelli, M., Falcone, R., Paris, I., Lauro, S., & Marchetti, P. (2014). Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know. Anticancer Research, 34(10), 5241-5250.